NADIM II: Neo-Adjuvant Immunotherapy (NADIMII)

• ClinicalTrials.gov Identifier: NCT03838159
• Recruitment Status: Active, not recruiting
• First Posted: February 12, 2019
• Last Update Posted: January 18, 2024
• Sponsor: Fundación GECP
• Information provided by (Responsible Party): Fundación GECP

Study Description

Brief Summary:

This is an open-label, randomised, two-arm, phase II, multi-centre clinical trial.

90 patients will be enrolled in this trial to examine the pathological Complete Response defined as the absence of residual tumor in lung and lymph nodes comparing patients treated with chemo-immunotherapy versus chemotherapy alone.

Condition or disease	Intervention/treatment	Phase
Non Small Cell Lung Cancer	Drug: Paclitaxel; Drug: Carboplatin; Drug: Nivolumab	Phase 2

Detailed Description:

This is an open-label, randomised, two-arm, phase II, multi-centre clinical trial.

Patients randomised to the experimental arm will receive Nivolumab 360mg + Paclitaxel 200mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days as neoadjuvant treatment followed by surgery and 6 months of adjuvant treatment with Nivolumab 480 mg Q4W. Patients randomized to the control arm will receive Paclitaxel 200mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days followed by surgery.

The primary objective is pathological Complete Response (pCR) defined as the absence of residual tumor in lung and lymph nodes comparing patients treated with chemo-immunotherapy versus chemotherapy alone.

Patient accrual is expected to be completed within 3 years excluding a run-in-period of 3 months. Treatment and follow-up are expected to extend the study duration to a total of 8.5 years. Patients will be followed 5 years after adjuvant treatment or surgery. The study will end once survival follow-up has concluded.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 90 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
• Actual Study Start Date: May 15, 2019
• Estimated Primary Completion Date: November 30, 2027
• Estimated Study Completion Date: November 30, 2028

Arms and Interventions

Arm	Intervention/treatment
Experimental: Experimental: Neo-Adjuvant Immunotherapy; Neoadjuvant treatment (200 mg/m3 Paclitaxel+ AUC5 Carboplatin+ 360 mg Nivolumab) will start within 1-3 days from randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.; Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3) .; Adjuvant treatment:Nivolumab: 480 mg Q4W (+/- 3 days) for 6 months (6 cycles). Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+ 7 days) from surgery and for 6 months.	Drug: Paclitaxel; Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml. The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known. In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected.; Other Name: Taxol; Drug: Carboplatin; Carboplatin must be administered at the end of the Paclitaxel infusion; Other Name: Paraplatin; Drug: Nivolumab; Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. The administration of nivolumab infusion must be completed within 24 hours of preparation.; Other Name: Opdivo
Active Comparator: Control: Neo-Adjuvant Chemotherapy; Neoadjuvant treatment (200mg/m3 Paclitaxel+ AUC5 Carboplatin). It will start within 1-3 days from randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.; Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)	Drug: Paclitaxel; Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml. The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known. In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected.; Other Name: Taxol; Drug: Carboplatin; Carboplatin must be administered at the end of the Paclitaxel infusion; Other Name: Paraplatin

Outcome Measures

Primary Outcome Measures :

1. Evaluation of the pathological complete response (pCR) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 45 months. ]
   The pathological complete response is defined as the absence of residual tumor in lung and lymph nodes in patients treated with chemo-immunotherapy versus patients treated with chemotherapy alone.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Previously untreated patients with histologically- or cytologically- documented NSCLC who present stage IIIA disease (according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and also, potentially resectable locally advanced NSCLC patients' stage IIIB with T3N2 disease according to 8th edition can be included.

   • PET/CT including IV contrast (CT of diagnostic quality) will be performed at baseline (28 days +10 before randomization)
2. Tumor should be considered resectable before study entry by a multidisciplinary team
3. ECOG (Performance status) 0-1

4. Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to randomization.

   i. Neutrophils ≥ 1500×109/L ii. Platelets ≥ 100 x×109/L iii. Hemoglobin > 9.0 g/dL iv. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min v. AST/ALT ≤ 3 x ULN vi. Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) vii. The patients need to have a forced expiratory volume (FEV1) ≥ 1.2 liters or >40% predicted value viii. INR/APTT within normal limits

5. All patients are notified of the investigational nature of this study and signed a written informed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention
6. Patients aged > 18 years
7. Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must have a negative serum or urine pregnancy test within 7 days before randomization.
8. All sexually active men and women of childbearing potential must use an effective contraceptive method (two barrier methods or a barrier method plus a hormonal method) during the study treatment and for a period of at least 12 months following the last administration of trial drugs
9. Patient capable of proper therapeutic compliance and accessible for correct follow-up
10. Measurable or evaluable disease (according to RECIST 1.1 criteria)

Exclusion Criteria:

1. All patients carrying activating mutations in the TK domain of EGFR or any variety of alterations in the ALK gene.
2. Patients with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement or unexpected conditions of recurrence in the absence of an external trigger are allowed to be included.
3. Patients with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
4. Patients with a history of interstitial lung disease cannot be included if they have symptomatic ILD (Grade 3-4) and/or poor lung function. In case of doubt please contact trial team.
5. Patients with other active malignancy requiring concurrent intervention and/or concurrent treatment with other investigational drugs or anti-cancer therapy
6. Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.
7. Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
8. Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
9. Patients with positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
10. Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
11. Patients with history of allergy to study drug components excipients
12. Women who are pregnant or in the period of breastfeeding
13. Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study

Contacts and Locations

Locations

Spain

ICO Badalona

Badalona, Barcelona, Spain, 08916

ICO Hospitalet

Hospitalet de Llobregat, Barcelona, Spain, 08908

Hospital Universitario Insular de Gran canaria

Las Palmas De Gran Canaria, Gran Canaria, Spain, 35016

Complejo Hospitalario Universitario A Coruña

A Coruña, La Coruña, Spain, 15006

Hospital Universitario Puerta de Hierro

Majadahonda, Madrid, Spain, 28222

Complejo Hospitalario Universitario de Vigo

Vigo, Pontevedra, Spain, 36036

Hospital Universitario de Cruces

Baracaldo, Vizcaya, Spain, 48903

Hospital General de Alicante

Alicante, Spain, 03010

Hospital Universitari Dexeus

Barcelona, Spain, 08028

Hospital Universitari Vall d' Hebron

Barcelona, Spain, 08035

Hospital Clínic de Barcelona

Barcelona, Spain, 08036

Hospital de Sant Pau

Barcelona, Spain, 08041

Hospital Universitario Reina Sofía

Córdoba, Spain, 14004

Hospital Dr. Josep Trueta

Girona, Spain, 17007

Hospital Clínico San Carlos

Madrid, Spain, 28040

Hospital Universitario Fundación Jiménez Díaz

Madrid, Spain, 28040

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Hospital Universitario La Paz

Madrid, Spain, 28046

Hospital General Universitario de Málaga

Málaga, Spain, 29010

Hospital Clínico de Salamanca

Salamanca, Spain, 37007

Hospital Virgen del Rocío

Sevilla, Spain, 41013

Hospital Clínico Universitario de Valencia

Valencia, Spain, 46010

Hospital General de Valencia

Valencia, Spain, 46014

Hospital Clínico Universitario de Valladolid

Valladolid, Spain, 47003

Hospital Clínico Lozano Blesa

Zaragoza, Spain, 50009

Sponsors and Collaborators

Fundación GECP

Investigators

• Principal Investigator: Mariano Provencio, MD; Hospital Puerta del Hierro

More Information

Additional Information:

Web page of the sponsor where users can find more information about Fundación GECP studies 

• Responsible Party: Fundación GECP
• ClinicalTrials.gov Identifier: NCT03838159
• Other Study ID Numbers: GECP 18/02_NADIM II; 2018-004515-45 ( EudraCT Number )
• First Posted: February 12, 2019
• Last Update Posted: January 18, 2024
• Last Verified: January 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Fundación GECP:

Inmunotherapy; Resectable stage IIIA; Adjuvant treatment

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Paclitaxel; Carboplatin; Nivolumab; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors